Previous 10 | Next 10 |
Summary Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies. While I have already reported on Viatris' ever-changing portfolio, in this ar...
Advent International's Zentiva generics business and Bain-backed drugmaker Stada Arzneimittel are evaluating offers for Viatris Inc.'s ( NASDAQ: VTRS ) consumer-health assets, which could see €3billion in a sale. The European over-the-counter portfolio is attracting possib...
A panel of the European Medicines Agency (EMA) recommended granting approval to Viatris ( NASDAQ: VTRS ) drug Dapagliflozin Viatris to treat type 2 diabetes mellitus, heart failure and chronic kidney disease. Dapagliflozin Viatris is a generic of AstraZeneca's ( NASDAQ: ...
Summary In the fourth quarter of 2022, the Miller Income Strategy returned 11.68%, while the benchmark ICE BofA US High Yield Index was up 3.98%. While China’s reopening stimulates aggregate global demand, it also unclogs global supply chains, thereby easing pricing pressures aro...
Summary Investing is a process of learning and growing; I look back at the knowledge I have gained so far on my journey. My three main blunders were thinking in dividends only, paying any price and losing patience. In 2022, my articles have returned an average of 8.84% vs. the S&...
Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...
If you want your portfolio to cut you a consistent check to use as passive income every quarter from here on out, you'll need to load up on high-quality dividend stocks that'll stand the test of time. And if you want that passive income to come from a decent return, the recent pullback in the...
Summary Viatris has seen a disappointing performance since its 2019 mega tie-up. Sales and EBITDA have fallen a bit, as leverage has fallen a bit further. The overall performance has been disappointing, but valuations have compressed further, leaving me wondering why recent deals ha...
Last December, Viatris (NASDAQ: VTRS) and Kindeva Drug Delivery lost in court against AstraZeneca (NASDAQ: AZN) over a patent dispute regarding one of the latter's patents for its asthma and chronic obstructive pulmonary disease (COPD) treatment Symbicort. This extended the la...
Viatris Inc. (VTRS) 41st Annual J.P. Morgan Healthcare Conference January 11, 2023 06:00 PM ET Company Participants Michael Goettler - CEO Rajiv Malik - President Jeffrey Nau - Head, Eye Care Conference Call Participants Chris Schott - JPMorgan Presen...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...